Natural Resources for Human Health
eISSN: 2583-1194

Original Research

Received 11 Aug 2024
Revised 07 Sep 2024
Accepted 26 Sep 2024

Natural Resources for Human Health 2024, Vol. 4 (1s): 176-185

KEYWORDS:
Drug-Drug Interactions; Pharmacy Evaluation; Chronic Disease Therapies; Prosthodontics; Restorative Dentistry; Medication Safety.

Pharmacy Evaluation of Potential Drug-Drug Interactions Between Dental Medications and Chronic Disease Therapies in Prosthodontic and Restorative Dental Care 2024

Azmi Eid Alsubhi[1], Abdulaziz Abdullah Alhazmi[2], Reham Ahmed Alemam[3], Khaled Ali Babalgeth[4], Shatha Mohammed Rmbo[5], Hifaa Abdullah Alotaibi[6], Fayhaa Saleh Allehyani[7], Bayan Ahmed Bakhsh[8], Ibrahim Mohammed Ali Mohammed[9], Mohammed Abdullah Allehyani[10], Naif Otaiwy Allehyani[11], Hussam Saud Alharbi[12]

[1,2,3,4,5,6,7,8,9,10,11,12]Doctor of Pharmacy & Pharmacists & Pharmacy technicians
Hera general hospital, Makkah, Saudi Arabia
Email Authors: Alsubhiazmi@yahoo.com

ABSTRACT:

Background: The rising prevalence of chronic systemic diseases among patients seeking prosthodontic and restorative dental care substantially increases the likelihood of concurrent pharmacotherapy. When short-term dental medications are prescribed alongside long-term systemic maintenance therapies, medically complex patients face heightened risks of potential drug-drug interactions (pDDIs).

Objectives: This pharmacy-led evaluation systematically analyzes the pharmacokinetic mechanisms, pharmacodynamic pathways, clinical severity, and management strategies of pDDIs occurring between commonly prescribed dental medications and chronic disease therapies within prosthodontic and restorative dental practice.

Methods: A comprehensive pharmacological evaluation was conducted examining four core dental pharmacotherapy classes—analgesics and anti-inflammatory agents, antimicrobials, local anesthetics with vasoconstrictors, and antifungals—against major chronic therapeutic regimens prescribed for cardiovascular, endocrine, hematologic, renal, and neurological disorders. Interactions were stratified by clinical risk severity and underlying metabolic pathways.

Results: High-priority pDDIs predominantly involve non-steroidal anti-inflammatory drugs (NSAIDs) interacting with antihypertensive regimens, vitamin K antagonists, direct oral anticoagulants (DOACs), and antiplatelet agents, resulting in attenuated blood pressure control, acute kidney injury, or major hemorrhage. Macrolide and azole antimicrobials demonstrate potent cytochrome P450 (CYP3A4 and CYP2C9) enzymatic inhibition with statins, oral hypoglycemics, and warfarin. Additionally, vasoconstrictors in local anesthetic formulations present significant pharmacodynamic hazards in patients receiving non-selective beta-blockers or tricyclic antidepressants.

Conclusions: Potential drug-drug interactions represent a frequent, clinically consequential, and preventable hazard in prosthodontic and restorative dental care.

Natural Resources for Human Health
eISSN: 2583-1194

Integrating structured pharmacy-led medication reconciliation and interdisciplinary prescribing protocols within general hospital dental departments is vital to safeguard patient safety and optimize therapeutic outcomes.

1. INTRODUCTION

Global demographic shifts characterized by increased life expectancy have transformed the clinical profile of populations seeking oral healthcare. Older adults and medically complex individuals now represent a substantial proportion of patients presenting to outpatient dental departments for specialized rehabilitative procedures. Within prosthodontic and restorative dentistry, clinical interventions frequently span multiple appointments and encompass fixed and removable dental prostheses, endosseous implant placement, complex endodontic therapy, crown lengthening, and periodontal surgery. Unlike younger, healthy cohorts, patients requiring extensive oral rehabilitation commonly exhibit chronic multimorbidity, including essential hypertension, ischemic heart disease, atrial fibrillation, diabetes mellitus, dyslipidemia, chronic kidney disease, and osteoporosis.

The longitudinal management of these systemic illnesses routinely necessitates polypharmacy, broadly defined in pharmacotherapeutic literature as the concurrent daily administration of five or more distinct medications. When acute or perioperative dental pharmacotherapy is superimposed upon an established chronic medication regimen, the probability of encountering a potential drug-drug interaction (pDDI) escalates exponentially. In general hospital outpatient dental clinics, prescriptions are typically issued for short durations—ranging from three to ten days—to alleviate postoperative pain, eradicate odontogenic infections, or control localized mucosal inflammation. However, pharmacokinetic enzyme inhibition and pharmacodynamic receptor antagonism often manifest rapidly within 24 to 72 hours of co-administration, meaning even brief exposure to an interacting dental agent can precipitate severe physiological decompensation, emergency hospitalization, or surgical failure.

Despite the clinical gravity of these pharmacological hazards, comprehensive medication reconciliation remains inconsistently implemented in routine dental workflows. Dental practitioners focus primarily on biomechanical precision, surgical execution, and restorative aesthetics, frequently relying on patient self-reporting during initial intake interviews to document systemic medication histories. Empirical pharmacy evaluations demonstrate that patient-reported medication lists frequently omit generic drug names, exact dosages, over-the-counter analgesics, and recently modified cardiovascular or antithrombotic regimens. Conversely, hospital pharmacists possess specialized expertise in clinical pharmacokinetics, cytochrome P450 (CYP450) metabolic pathways, drug transporter kinetics, and therapeutic drug monitoring, positioning them uniquely to detect and mitigate medication-related risks prior to dispensing.

Existing biomedical literature has predominantly examined prescribing patterns in general dental practice or focused narrowly on isolated drug classes such as antibiotics or local anesthetics. There remains a distinct paucity of structured pharmacy evaluations specifically tailored to the pharmacological complexities of prosthodontic and restorative dental populations, where older age, surgical tissue trauma, and chronic polypharmacy converge. Therefore, this paper provides a rigorous, generalizable pharmacy evaluation of the mechanisms, clinical consequences, and evidence-based mitigation strategies for pDDIs between commonly prescribed dental medications and chronic disease therapies in prosthodontic and restorative dental care.

2. METHODOLOGY OF THE PHARMACY EVALUATION

To establish an objective, reproducible, and clinically actionable pharmacological assessment applicable to pharmacy departments within general hospital settings, this evaluation systematically cross-examined two primary therapeutic domains: Standard Dental Pharmacotherapy and Chronic Systemic Maintenance Therapies.

2.1 Scope of Dental Medications Evaluated

The pharmacological review encompassed four principal medication classes routinely prescribed or administered chairside during prosthodontic, implant, and restorative procedures:

- **Analgesics and Anti-Inflammatory Agents:** Non-selective non-steroidal anti-inflammatory drugs (NSAIDs; ibuprofen, diclofenac, naproxen, ketoprofen, mefenamic acid), cyclooxygenase-2 (COX-2) selective inhibitors (celecoxib), centrally acting non-opioid analgesics (acetaminophen/paracetamol), and opioid analgesics (codeine, tramadol).
- **Systemic Antimicrobials:** Penicillins and beta-lactamase inhibitor combinations (amoxicillin, amoxicillin-clavulanate), first-generation cephalosporins (cephalexin), lincosamides (clindamycin), macrolides (azithromycin, clarithromycin, erythromycin), nitroimidazoles (metronidazole), and tetracyclines (doxycycline).
- **Local Anesthetics and Vasoconstrictors:** Amide local anesthetics (lidocaine, articaine, mepivacaine, bupivacaine) formulated with adrenergic vasoconstrictors (epinephrine 1:100,000 or 1:200,000; levonordefrin 1:20,000) as well as plain vasoconstrictor-free preparations.
- **Antifungal and Oral Antiseptic Agents:** Systemic triazoles (fluconazole), topical imidazoles (miconazole oral gel, clotrimazole troches), polyene antifungals (nystatin oral suspension), and biguanide antiseptics (chlorhexidine gluconate mouthrinse).

2.2 Scope of Chronic Disease Therapies Evaluated

Chronic systemic drug classes were selected based on high epidemiological prevalence among adult and geriatric cohorts undergoing oral rehabilitation:

- **Cardiovascular and Renal Agents:** Angiotensin-converting enzyme (ACE) inhibitors (lisinopril, enalapril, ramipril), angiotensin II receptor blockers (ARBs; losartan, valsartan, candesartan), cardioselective and non-selective beta-adrenergic blockers (bisoprolol, metoprolol, propranolol, carvedilol), dihydropyridine and non-dihydropyridine calcium channel blockers (amlodipine, nifedipine, diltiazem, verapamil), loop and thiazide diuretics (furosemide, hydrochlorothiazide), cardiac glycosides (digoxin), and HMG-CoA reductase inhibitors (simvastatin, atorvastatin, rosuvastatin).
- **Antithrombotic and Hemostatic Modulators:** Vitamin K antagonists (warfarin), direct oral anticoagulants (DOACs; apixaban, rivaroxaban, dabigatran, edoxaban), and antiplatelet agents (low-dose acetylsalicylic acid/aspirin, clopidogrel, ticagrelor).
- **Endocrine and Metabolic Therapies:** Basal and bolus insulin formulations, sulfonylureas (gliclazide, glimepiride, glibenclamide), biguanides (metformin), dipeptidyl peptidase-4 (DPP-4) inhibitors (sitagliptin), and sodium-glucose cotransporter-2 (SGLT2) inhibitors (empagliflozin, dapagliflozin).
- **Neurological, Psychiatric, and Bone-Modifying Agents:** Selective serotonin reuptake inhibitors (SSRIs; sertraline, fluoxetine, escitalopram), serotonin-norepinephrine reuptake inhibitors (SNRIs; venlafaxine, duloxetine), tricyclic antidepressants (TCAs; amitriptyline), mood stabilizers (lithium), anticonvulsants (carbamazepine, phenytoin, valproate), immunosuppressants (methotrexate), and antiresorptive therapies (oral and intravenous bisphosphonates, denosumab).

2.3 Pharmacological Classification and Risk Stratification

Every clinically recognized dental-chronic drug pairing was evaluated across three analytical dimensions:

- **Pharmacokinetic Pathways:** Alterations in gastrointestinal absorption via chelation or pH modification, displacement from plasma albumin binding sites, inhibition or induction of hepatic cytochrome P450 isoenzymes (principally CYP3A4, CYP2C9, CYP2C19, and CYP2D6), modulation of P-glycoprotein (P-gp) efflux transporters, and competitive inhibition of active renal tubular secretion.
- **Pharmacodynamic Mechanisms:** Additive or synergistic toxicity (e.g., dual impairment of hemostasis or overlapping QT-interval prolongation), physiological antagonism at vascular or renal receptor sites, and neurotransmitter reuptake potentiation.
- **Clinical Severity Tiering:** Interactions were categorized as Major (high risk of life-threatening toxicity or permanent organ impairment; contraindicated or requiring mandatory therapeutic substitution), Moderate (potential for clinical

deterioration; requiring dosage modification, temporal spacing, or targeted laboratory monitoring), or Minor (minimal clinical consequence; manageable through routine patient counseling).

3. COMPREHENSIVE PHARMACOLOGICAL ANALYSIS OF PDDIS

3.1 Analgesics and Anti-Inflammatory Agents

Effective postoperative analgesia is indispensable following crown preparation, subgingival margin placement, endodontic instrumentation, and dental implant surgery. Nevertheless, analgesics—particularly non-selective NSAIDs—account for the highest proportion of severe adverse drug interactions among chronically ill dental patients.

3.1.1 NSAIDs and Antihypertensive / Renoprotective Regimens

Non-selective NSAIDs inhibit both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes within the renal cortex and medulla, suppressing the biosynthesis of vasodilatory and natriuretic prostaglandins (PGE2 and PGI2). Under physiological conditions, these prostaglandins maintain afferent arteriolar dilation to preserve glomerular filtration pressure, particularly in patients with underlying renal insufficiency or volume depletion. Concurrently, ACE inhibitors and ARBs dilate the efferent glomerular arteriole, while diuretics reduce intravascular volume. Co-administration of an NSAID with an ACE inhibitor or ARB and a diuretic creates a synergistic hemodynamic insult known clinically as the 'Triple Whammy' effect.

Clinically, even a short 5-to-7-day postoperative course of ibuprofen (400–600 mg three times daily) or diclofenac (50 mg three times daily) can elevate mean systolic blood pressure by 5 to 10 mmHg, precipitate peripheral edema, and trigger acute kidney injury (AKI) characterized by abrupt rises in serum creatinine and hyperkalemia. From a pharmacy perspective, acetaminophen (paracetamol) serves as the safest first-line analgesic for patients receiving multi-drug antihypertensive regimens or presenting with stage 3 or higher chronic kidney disease. When anti-inflammatory therapy is strictly unavoidable, pharmacists should recommend limiting NSAID duration to three days or fewer, ensuring adequate hydration, and avoiding concurrent use in patients on triple antihypertensive therapy.

3.1.2 NSAIDs and Antithrombotic Agents (Warfarin, DOACs, and Antiplatelets)

Patients with prosthetic heart valves, atrial fibrillation, coronary stents, or prior cerebrovascular events rely on continuous antithrombotic therapy. Prescribing systemic NSAIDs in these populations introduces a dual-pathway hemorrhagic hazard. First, NSAIDs reversibly inhibit platelet COX-1, suppressing thromboxane A2 synthesis and impairing primary platelet aggregation. Second, NSAIDs exert direct topical acidic injury and inhibit cytoprotective gastric mucosal prostaglandins, predisposing patients to mucosal ulceration. When combined with warfarin, apixaban, rivaroxaban, or clopidogrel, the risk of severe upper gastrointestinal bleeding and prolonged postoperative hemorrhage at surgical or gingival retraction sites increases three- to six-fold.

Furthermore, a critical pharmacodynamic antagonism occurs between ibuprofen and low-dose cardioprotective aspirin (75–100 mg daily). Ibuprofen occupies the hydrophobic channel of platelet COX-1 reversibly, sterically blocking aspirin from accessing and irreversibly acetylating the Serine-529 residue. Consequently, patients taking ibuprofen prior to their morning aspirin dose lose cardioprotective antiplatelet inhibition. Pharmacists must counsel patients on low-dose aspirin to avoid routine ibuprofen use, or if occasional dosing is required, to administer immediate-release aspirin at least 2 hours before or 8 hours after ibuprofen ingestion. For patients on oral anticoagulants or dual antiplatelet therapy, systemic NSAIDs should be strictly avoided in favor of scheduled acetaminophen (up to 3000 mg/day in adults with normal hepatic function) or short-course tramadol for severe postoperative pain.

3.1.3 NSAIDs and Narrow-Therapeutic-Index Drugs (Lithium and Methotrexate)

NSAID-induced reductions in renal prostaglandin synthesis decrease glomerular filtration rate and directly compete with organic anion transporters in the proximal renal tubule, impairing the clearance of lithium (used in bipolar disorder) and low-dose weekly methotrexate (used in rheumatoid arthritis and psoriasis). Within 48 to 96 hours of initiating an NSAID for dental pain, serum lithium levels can rise by 25% to 60%, precipitating neurological toxicity manifested by coarse tremor, ataxia, dysarthria, confusion, and arrhythmias. Similarly, delayed methotrexate elimination can lead to severe pancytopenia and mucositis. Pharmacy intervention mandates strict avoidance of systemic NSAIDs in patients prescribed lithium or methotrexate, utilizing acetaminophen or localized topical anesthetic agents instead.

3.1.4 Tramadol and Serotonergic Antidepressants (SSRIs / SNRIs)

When NSAIDs are contraindicated, clinicians occasionally prescribe tramadol for moderate-to-severe dental pain. However, tramadol possesses dual mechanisms: weak mu-opioid receptor agonism and inhibition of neuronal serotonin and norepinephrine reuptake. Co-administration with SSRIs (e.g., sertraline, fluoxetine) or SNRIs (e.g., venlafaxine) creates an additive serotonergic burden, increasing the risk of serotonin syndrome (autonomic instability, hyperreflexia, clonus, agitation) and lowering the seizure threshold. Additionally, potent CYP2D6 inhibitors such as fluoxetine and paroxetine block the bioactivation of tramadol (and codeine) into its active O-desmethylated opioid metabolite, resulting in analgesic failure. Pharmacists should verify antidepressant profiles before recommending tramadol or codeine, preferring optimized acetaminophen dosing or non-CYP2D6-dependent analgesics.

3.2 Antimicrobials in Endodontic, Periodontal, and Implant Therapy

Systemic antibiotics are frequently prescribed in prosthodontic and restorative settings to treat acute periapical abscesses, spreading odontogenic cellulitis, severe periodontitis, and peri-implantitis. Several dental antimicrobials act as potent modulators of hepatic cytochrome P450 enzymes and intestinal drug transporters.

3.2.1 Metronidazole and Warfarin / Lithium

Metronidazole provides essential anaerobic coverage in acute odontogenic and periodontal infections, frequently prescribed alone or alongside amoxicillin. However, metronidazole is a potent inhibitor of hepatic CYP2C9, the primary enzyme responsible for metabolizing the biologically more potent S-enantiomer of warfarin. Co-administration markedly prolongs warfarin elimination half-life, causing supratherapeutic International Normalized Ratio (INR) elevations within 48 to 72 hours and exposing patients to spontaneous gastrointestinal, intracranial, or oral hemorrhage. Whenever clinically feasible, pharmacists should recommend alternative anaerobic regimens—such as amoxicillin-clavulanate or clindamycin—in warfarin-anticoagulated patients. If metronidazole is clinically indispensable, close coordination with the anticoagulation service is mandatory to implement an empirical 25% to 30% warfarin dose reduction and repeat INR testing within three days.

3.2.2 Macrolides (Clarithromycin, Erythromycin) and Cardiovascular Regimens

For patients reporting penicillin allergies, macrolide antibiotics are periodically selected. Clarithromycin and erythromycin are strong mechanism-based inhibitors of both hepatic/intestinal CYP3A4 and P-glycoprotein (P-gp) efflux transporters. Co-administration with CYP3A4-metabolized HMG-CoA reductase inhibitors—specifically simvastatin and atorvastatin—can elevate systemic statin exposure up to tenfold, precipitating severe myopathy, elevated creatine kinase, and life-threatening rhabdomyolysis with acute renal failure. Furthermore, concurrent use of clarithromycin or erythromycin with dihydropyridine calcium channel blockers (amlodipine, nifedipine) inhibits vascular drug clearance, resulting in profound hypotension, reflex tachycardia, and acute kidney injury. In patients taking DOACs (rivaroxaban, apixaban), dual CYP3A4 and P-gp inhibition substantially increases plasma anticoagulant concentrations and bleeding risk. Pharmacy evaluation dictates substituting clarithromycin/erythromycin with azithromycin (which exhibits negligible CYP3A4 or P-gp inhibition) or clindamycin, or temporarily withholding simvastatin/atorvastatin during the short antibiotic course.

3.2.3 Tetracyclines and Multivalent Cations

Doxycycline is widely utilized as an antimicrobial and host-modulating adjunct in periodontal and peri-implant therapy. In the gastrointestinal lumen, tetracyclines strongly chelate divalent and trivalent metallic cations—including calcium (Ca^{2+}), magnesium (Mg^{2+}), iron (Fe^{2+}/Fe^{3+}), aluminum (Al^{3+}), and zinc (Zn^{2+})—found in osteoporosis supplements, antacids, multivitamins, and dairy products. The resulting insoluble chelates cannot cross the intestinal epithelium, reducing doxycycline systemic bioavailability by up to 80% and causing clinical treatment failure. Pharmacists must provide explicit counseling instructing patients to separate doxycycline doses from cation-containing supplements or antacids by at least 2 to 3 hours.

3.3 Antifungal Agents in Removable Prosthodontics

Chronic atrophic candidiasis (denture stomatitis) affects a substantial percentage of patients wearing complete or partial removable prostheses. Topical azole antifungals are commonly prescribed to eradicate Candida albicans colonization on palatal mucosa and acrylic denture surfaces.

Miconazole oral gel is frequently perceived by clinicians as a purely local therapy devoid of systemic drug interactions. However, sufficient transmucosal and gastrointestinal absorption occurs during topical oral application to potently inhibit hepatic CYP2C9 and CYP3A4 isoenzymes. In patients stabilized on warfarin, topical miconazole oral gel has been repeatedly documented to cause dramatic INR spikes (> 8.0) and severe hemorrhage. Similarly, CYP2C9 inhibition impairs the hepatic clearance of sulfonylurea oral hypoglycemics (gliclazide, glimepiride, glibenclamide), triggering prolonged, severe hypoglycemia. Pharmacy evaluation strongly recommends substituting miconazole oral gel with topical nystatin oral suspension (which is virtually unabsorbed from the gastrointestinal tract and lacks CYP450 activity) in patients receiving warfarin or sulfonylureas.

3.4 Local Anesthetics and Adrenergic Vasoconstrictors

Profound local anesthesia is a prerequisite for atraumatic tooth preparation, subgingival impression making, and implant osteotomy. Epinephrine is routinely incorporated into amide local anesthetic cartridges to prolong pulpal and soft-tissue anesthesia and maintain hemostasis.

In patients prescribed non-selective beta-adrenergic blockers (such as propranolol, nadolol, timolol, or carvedilol) for hypertension, migraine prophylaxis, or essential tremor, vascular beta-2 receptors mediating skeletal muscle vasodilation are pharmacologically blocked. When exogenous epinephrine is absorbed systemically from highly vascular oral tissues, unopposed alpha-1 adrenergic receptor stimulation induces rapid peripheral vasoconstriction. This triggers an abrupt, severe spike in systolic and diastolic blood pressure accompanied by reflex vagal bradycardia. Pharmacy safety protocols advise limiting total epinephrine administration to a maximum of 0.04 mg per appointment (equivalent to two 1.8 mL cartridges of 1:100,000 epinephrine), employing slow injection with frequent aspiration to prevent intravascular delivery, or selecting a vasoconstrictor-free anesthetic formulation (such as 3% mepivacaine plain) for restorative procedures of short-to-moderate duration.

3.5 Antiresorptive Bone Therapies and Dental Surgical / Restorative Procedures

While not a classical pharmacokinetic drug-drug interaction, the pharmacodynamic intersection between chronic antiresorptive medications (oral/intravenous bisphosphonates such as alendronate, zoledronic acid, and RANKL inhibitors such as denosumab) and invasive prosthodontic/restorative interventions warrants rigorous pharmacy verification. Patients receiving systemic corticosteroids alongside antiresorptives face compounded risks of impaired bone remodeling and medication-related osteonecrosis of the jaw (MRONJ) following extractions, implant placement, or ill-fitting denture trauma. Pharmacy reconciliation ensures early identification of antiresorptive duration and cumulative exposure prior to surgical restorative planning.

4. SUMMARY MATRIX OF HIGH-PRIORITY PDDIS IN PROSTHODONTIC AND RESTORATIVE CARE

Table 1 consolidates the highest-priority potential drug-drug interactions identified in this pharmacy evaluation, outlining underlying mechanisms, clinical consequences, severity classifications, and evidence-based pharmacist interventions.

Table 1. Clinical Pharmacy Risk Matrix of Potential Drug-Drug Interactions Between Dental Medications and Chronic Disease Therapies.

Dental Medication	Chronic Therapy	Mechanism & Severity	Clinical Outcome	Pharmacist Intervention
NSAIDs (Ibuprofen, Diclofenac, Naproxen)	ACE Inhibitors / ARBs + Diuretics	Pharmacodynamic: Renal PG inhibition; reduced GFR [MAJOR]	Acute kidney injury (Triple Whammy); loss of BP control	Substitute with acetaminophen; limit NSAIDs to ≤ 3 days if strictly required

Dental Medication	Chronic Therapy	Mechanism & Severity	Clinical Outcome	Pharmacist Intervention
NSAIDs (Non-selective)	Warfarin, DOACs (Apixaban, Rivaroxaban), Clopidogrel	Pharmacodynamic: Additive platelet inhibition + mucosal injury [MAJOR]	Severe upper GI bleeding; prolonged oral surgical hemorrhage	Avoid systemic NSAIDs; prescribe acetaminophen or short-course tramadol
Ibuprofen	Low-Dose Aspirin (75–100 mg daily)	Pharmacodynamic: Competitive steric block of platelet COX-1 [MODERATE]	Loss of cardioprotective antiplatelet efficacy	Administer aspirin ≥ 2 hours before or ≥ 8 hours after ibuprofen
NSAIDs	Lithium / Low-Dose Methotrexate	Pharmacokinetic: Reduced renal tubular clearance [MAJOR]	Lithium neurotoxicity; methotrexate myelosuppression	Strictly avoid NSAIDs; utilize acetaminophen or topical anesthetics
Tramadol / Codeine	SSRIs / SNRIs (Fluoxetine, Paroxetine, Sertraline)	Pharmacodynamic / CYP2D6 inhibition [MAJOR / MODERATE]	Serotonin syndrome; reduced analgesic bioactivation	Avoid combination with strong CYP2D6 inhibitors; use acetaminophen
Metronidazole	Warfarin	Pharmacokinetic: Potent hepatic CYP2C9 inhibition [MAJOR]	Markedly elevated INR within 48–72 hours; hemorrhage	Use amoxicillin-clavulanate or clindamycin; or reduce warfarin & monitor INR
Clarithromycin / Erythromycin	Simvastatin, Atorvastatin	Pharmacokinetic: Potent CYP3A4 enzymatic inhibition [MAJOR]	Severe myopathy and rhabdomyolysis	Substitute with azithromycin or temporarily hold statin therapy
Clarithromycin / Erythromycin	Amlodipine, Nifedipine, Rivaroxaban	Pharmacokinetic: CYP3A4 and P-gp efflux inhibition [MAJOR]	Profound hypotension, edema, or DOAC-related bleeding	Substitute with azithromycin or non-interacting beta-lactam
Doxycycline	Calcium, Iron, Magnesium, Antacids	Pharmacokinetic: GI lumen chelation complexation [MODERATE]	Up to 80% drop in antibiotic absorption; treatment failure	Separate administration by at least 2 to 3 hours
Miconazole Oral Gel	Warfarin, Sulfonylureas (Gliclazide)	Pharmacokinetic: Systemic mucosal CYP2C9 inhibition [MAJOR]	Supratherapeutic INR spikes; severe prolonged hypoglycemia	Substitute with topical nystatin oral suspension

Dental Medication	Chronic Therapy	Mechanism & Severity	Clinical Outcome	Pharmacist Intervention
Epinephrine (in Local Anesthetics)	Non-Selective Beta-Blockers (Propranolol)	Pharmacodynamic: Unopposed α1-adrenergic vasoconstriction [MAJOR]	Acute hypertensive crisis with reflex bradycardia	Limit epinephrine to ≤ 0.04 mg or use 3% mepivacaine plain

5. DISCUSSION AND CLINICAL PHARMACY INTEGRATION FRAMEWORK

The pharmacological synthesis presented in this evaluation highlights a critical structural vulnerability in contemporary outpatient dental care delivery. Patients undergoing prosthodontic rehabilitation and complex restorative procedures disproportionately represent an aging demographic burdened by cardiovascular, metabolic, hemostatic, and renal comorbidities. While dental prescriptions are characteristically issued for brief durations, the biochemical mechanisms governing high-risk interactions—such as cytochrome P450 enzymatic inhibition by metronidazole, clarithromycin, and miconazole, or prostaglandin-mediated renal vasoconstriction by NSAIDs—occur rapidly upon systemic absorption. Consequently, the assumption that short-course dental pharmacotherapy carries negligible systemic risk is pharmacologically unfounded.

In general hospital settings, the operational and physical compartmentalization between outpatient dental clinics and central pharmacy services frequently impedes proactive clinical intervention. When dental prescriptions are transmitted to the outpatient pharmacy without linked diagnostic codes or access to the patient's longitudinal chronic medication profile, pharmacists are constrained to a reactive dispensing role rather than performing comprehensive clinical verification. Compounding this vulnerability, patients routinely perceive non-prescription dental analgesics (such as over-the-counter ibuprofen) and topical oral preparations (such as miconazole gel for denture stomatitis) as benign local remedies, rarely disclosing their use to primary care physicians, cardiologists, or anticoagulation clinics.

Furthermore, the clinical consequences of unrecognized pDDIs directly impact restorative and prosthodontic treatment outcomes. Uncontrolled postoperative hemorrhage precipitated by NSAID-anticoagulant co-administration can compromise surgical flap stability, delay soft-tissue healing around dental implants, and necessitate emergency hospital readmission. Similarly, acute hypertensive episodes triggered by unopposed epinephrine vasoconstriction in non-selective beta-blocker users endanger patient safety during lengthy crown preparation or impression appointments. Conversely, subtherapeutic antibiotic bioavailability caused by doxycycline-cation chelation can result in persistent peri-implant or endodontic infection, jeopardizing prosthetic prognosis.

5.1 Interdisciplinary Model for General Hospital Dental Departments

To mitigate preventable adverse drug events and bridge the collaborative gap between pharmacy services and prosthodontic/restorative dentistry, general hospitals should adopt a structured, four-pillar medication safety framework:

- **1. Standardized Pre-Procedural Medication Reconciliation:** Implement a mandatory, pharmacist-verified medication reconciliation workflow prior to initiating multi-visit prosthodontic, implant, or surgical restorative treatment plans. This process must systematically capture prescription maintenance therapies, over-the-counter analgesics, antacids, and herbal supplements, flagging high-risk agents such as warfarin, DOACs, antiplatelets, non-selective beta-blockers, and antiresorptives in the dental chart.
- **2. Integrated Electronic Health Record (EHR) Decision Support:** Configure hospital computerized provider order entry (CPOE) systems within outpatient dental clinics to automatically cross-screen newly ordered dental prescriptions against active chronic outpatient medication lists. Clinical decision support alerts should be stratified by clinical severity—presenting hard-stop or mandatory justification prompts exclusively for Major interactions—to prevent alert fatigue among dental practitioners.
- **3. Institutional Dental Prescribing Algorithms:** Establish joint pharmacy-and-therapeutics (P&T) approved prescribing guidelines tailored for medically compromised dental patients. These protocols should designate safe default

first-line alternatives (e.g., scheduled acetaminophen protocols for anticoagulated or hypertensive patients, azithromycin in place of clarithromycin for statin users, and nystatin suspension in place of miconazole gel for warfarin users).

- **4. Structured Patient Counseling and Interdisciplinary Communication:** Provide standardized written and verbal discharge counseling at the hospital pharmacy counter emphasizing analgesic timing (such as separating ibuprofen from low-dose aspirin), cation spacing with doxycycline, and warning signs of bleeding or hypotension. Establish direct communication channels between hospital pharmacists, prosthodontists, and managing physicians whenever dose adjustments or laboratory monitoring (e.g., INR checks) are warranted.

6. CONCLUSION

Potential drug-drug interactions between prescribed dental medications and chronic disease therapies represent a frequent, clinically consequential, and largely preventable threat to patient safety in prosthodontic and restorative dental care. High-risk interactions predominantly involve non-steroidal anti-inflammatory drugs, nitroimidazole and macrolide antimicrobials, topical azole antifungals, and epinephrine-containing local anesthetics interacting with cardiovascular, antithrombotic, and endocrine regimens. Embedding structured pharmacy-led medication evaluations, integrated electronic prescribing checks, and interdisciplinary clinical protocols within general hospital dental departments is essential to safeguard medically complex patients and elevate the quality of restorative oral healthcare.

REFERENCES

[1] Petersen PE, Yamamoto T. Improving the oral health of older people: the approach of the WHO Global Oral Health Programme. Community Dent Oral Epidemiol. 2005;33(2):81-92.

[2] Radfar L, Suresh L. Medical profile of a dental school patient population. J Dent Educ. 2007;71(5):682-686.

[3] Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995-2010. BMC Med. 2015;13:74.

[4] Becker DE. Adverse drug interactions in dental practice: interactions associated with analgesics, sedatives, and antimicrobials. Anesth Prog. 2011;58(1):31-41.

[5] Fitzgerald RJ, Pirmohamed M. Adverse drug reactions in dental practice: a review of mechanisms and clinical management. Br Dent J. 2007;203(8):459-466.

[6] Sturrock A, Preshaw PM, Hayes C, Wilkes S. Perceptions and attitudes of laypersons and healthcare professionals towards clinical pharmacists in dental settings: a qualitative study. BMJ Open. 2020;10(3):e035173.

[7] Hersh EV, Moore PA. Adverse drug interactions in dentistry. Periodontol 2000. 2008;46:109-142.

[8] Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ. 2013;346:e8525.

[9] Fournier JP, Sommet A, Durrieu G, Poutrain JC, Lapeyre-Mestre M, Montastruc JL. Drug interactions between antihypertensive drugs and non-steroidal anti-inflammatory drugs: a scoping review. J Hypertens. 2014;32(9):1745-1754.

[10] Schjerning Olsen AM, Gislason GH, McGettigan P, et al. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. JAMA. 2015;313(8):805-814.

[11] Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345(25):1809-1817.

[12] Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165(10):1095-1106.

[13] Patel AM, Shariff S, Bailey DG, et al. Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study. Ann Intern Med. 2013;158(12):869-876.

[14] Wright AJ, Gomes T, Mamdani MM, Horn JR, Juurlink DN. The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers. CMAJ. 2011;183(3):303-307.

[15] Pemberton MN, Oliver RJ, Theaker ED. Miconazole oral gel and drug interactions. Br Dent J. 2004;196(9):529-531.

[16] Yagiela JA. Adverse drug interactions in dental practice: interactions associated with vasoconstrictors. J Am Dent Assoc. 1999;130(5):701-709.

[17] Haas DA. An update on local anesthetics in dentistry. J Can Dent Assoc. 2002;68(9):546-551.

[18] Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons' position paper on medication-related osteonecrosis of the jaws—2022 update. J Oral Maxillofac Surg. 2022;80(5):920-943.